The combined use of enamel matrix proteins and a tetracycline‐coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra‐osseous defects

Abstract

The combined use of enamel matrix proteins and a tetracyclinecoated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects Sipos, P.M.; Loos, B.G.; Abbas, Frank; Timmerman, M.F.; Velden, U. van der CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 12-05-2018The combined use of enamel matrix proteins and a tetracyclinecoated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects AbstractObjectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel s ) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex s ). Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6-and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured. Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86 AE 0.75 mm, a mean gain in CAL of 1.28 AE 2.04 mm, a mean PBL gain of 1.63 AE 1.21 mm and a mean increase of recession (REC) of 1.56 AE 2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02 AE 1.55 mm, a mean gain in CAL of 1.65 AE 1.29 mm, a mean PBL gain of 1.58 AE 1.92 mm and a mean increase of REC of 1.38 AE 1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects. Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.

The Application of an Enamel Matrix Protein Derivative (Emdogain®) in Regenerative Periodontal Therapy: A Review

“…It was shown that all 3 regenerative treatment procedures resulted in a significantly higher improvement of the clinical parameters compared to the conventional flap surgery; however, combination therapy of EMD + GTR led to no additional improvement. Comparable results were also reported by others [117,118] . A prospective, controlled split-mouth study in 11 patients with a total of 12 pairs of intrabony defects evaluated the clinical response of EMD with or without a combination of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane at 6 and 12 months following therapy [118] .…”

“…Comparable results were also reported by others [117,118] . A prospective, controlled split-mouth study in 11 patients with a total of 12 pairs of intrabony defects evaluated the clinical response of EMD with or without a combination of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane at 6 and 12 months following therapy [118] . At 12 months, the mean CAL gain was 1.28 8 2.04 mm in the EMD group and 1.65 8 1.29 mm in the EMD + GTR group.…”

Enamel matrix protein derivatives: role in periodontal regeneration

“…It was shown that all three regenerative treatment procedures resulted in a significantly greater improvement in clinical parameters compared with conventional flap surgery; however, combination therapy of EMD + GTR led to no additional improvement. A prospective, controlled split-mouth study in 11 patients with a total of 12 pairs of intrabony defects evaluated the clinical response of EMD with or without a tetracycline-coated expanded polytetrafluoroethylene barrier membrane at 6 and 12 months following therapy 117. Several studies have evaluated the effect of a combination of EMD and various types of bone graft/bone substitute in the treatment of intrabony defects.…”

The effects of tetracycline-loaded silk fibroin membrane on proliferation and osteogenic potential of mesenchymal stem cells

“…Previous studies showed that TC-incorporation showed improved in vitro and/or in vivo results compared with original membranes [5,33e37]. However, other studies showed no additional benefits to TC-coated e-PTFE membrane for GTR result [38]. These differences may reflect the type of membrane material and TC released from the collagen membrane delayed degradation of the membrane because of anti-matrix metalloproteinasess and antibacterial properties [36,39,40].…”